StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.17−0.04 (-0.12%)

Close on Nov 18, 2026Market cap $6.85BP/E –Yield –

Immunovant net income

Net income is the profit left for shareholders after every expense, interest and tax.

Immunovant's net income for the twelve months ending Jun 30, 2026 was -$538.22M. For fiscal 2026 it was -$505.61M. The highest annual figure on record is -$28.60M in fiscal 2019.

Annual net income

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$505.61M–
FY2025Mar 31, 2025-$413.84M–
FY2024Mar 31, 2024-$259.34M–
FY2023Mar 31, 2023-$210.96M–
FY2022Mar 31, 2022-$156.73M–
FY2021Mar 31, 2021-$107.43M–
FY2020Mar 31, 2020-$66.39M–
FY2019Mar 31, 2019-$28.60M–

Quarterly net income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026-$153.22M–
Q4 FY2026CQ1 2026Mar 31, 2026-$147.86M–
Q3 FY2026CQ4 2025Dec 31, 2025-$110.64M–
Q2 FY2026CQ3 2025Sep 30, 2025-$126.50M–
Q1 FY2026CQ2 2025Jun 30, 2025-$120.61M–
Q4 FY2025CQ1 2025Mar 31, 2025-$106.45M–
Q3 FY2025CQ4 2024Dec 31, 2024-$111.12M–
Q2 FY2025CQ3 2024Sep 30, 2024-$109.12M–
Q1 FY2025CQ2 2024Jun 30, 2024-$87.15M–
Q4 FY2024CQ1 2024Mar 31, 2024-$75.32M–
Q3 FY2024CQ4 2023Dec 31, 2023-$51.42M–
Q2 FY2024CQ3 2023Sep 30, 2023-$58.66M–
Q1 FY2024CQ2 2023Jun 30, 2023-$73.94M–
Q4 FY2023CQ1 2023Mar 31, 2023-$59.43M–
Q3 FY2023CQ4 2022Dec 31, 2022-$63.23M–
Q2 FY2023CQ3 2022Sep 30, 2022-$47.93M–
Q1 FY2023CQ2 2022Jun 30, 2022-$40.37M–
Q4 FY2022CQ1 2022Mar 31, 2022-$47.17M–
Q3 FY2022CQ4 2021Dec 31, 2021-$41.39M–
Q2 FY2022CQ3 2021Sep 30, 2021-$37.70M–
Q1 FY2022CQ2 2021Jun 30, 2021-$30.47M–
Q4 FY2021CQ1 2021Mar 31, 2021-$28.16M–
Q3 FY2021CQ4 2020Dec 31, 2020-$31.78M–
Q2 FY2021CQ3 2020Sep 30, 2020-$20.79M–
Q1 FY2021CQ2 2020Jun 30, 2020-$26.71M–
Q4 FY2020CQ1 2020Mar 31, 2020-$31.85M–
Q1 FY2020CQ2 2019Jun 30, 2019-$20.06M–
Q4 FY2019CQ1 2019Mar 31, 2019-$450–
Q3 FY2019CQ4 2018Dec 31, 2018-$8.85M–
Q2 FY2019CQ3 2018Sep 30, 2018-$6.35M–
Q1 FY2019CQ2 2018Jul 6, 2018-$4.37M–

More Immunovant figures

See a number that looks wrong?